limonin-D-ring-lactonase | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
EC no. | 3.1.1.36 | ||||||||
CAS no. | 9031-17-8 | ||||||||
Databases | |||||||||
IntEnz | IntEnz view | ||||||||
BRENDA | BRENDA entry | ||||||||
ExPASy | NiceZyme view | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
Gene Ontology | AmiGO / QuickGO | ||||||||
|
The enzyme limonin-D-ring-lactonase (EC 3.1.1.36) catalyzes the reaction
This enzyme belongs to the family of hydrolases, specifically those acting on carboxylic ester bonds. The systematic name of this enzyme class is limonoate-D-ring-lactone lactonohydrolase. Other names in common use include limonin-D-ring-lactone hydrolase, and limonin lactone hydrolase.
Lactones are cyclic carboxylic esters, containing a 1-oxacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
6-Phosphogluconolactonase (EC 3.1.1.31, 6PGL, PGLS, systematic name 6-phospho-D-glucono-1,5-lactone lactonohydrolase) is a cytosolic enzyme found in all organisms that catalyzes the hydrolysis of 6-phosphogluconolactone to 6-phosphogluconic acid in the oxidative phase of the pentose phosphate pathway:
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata, a tree native to China used in traditional Chinese medicine. It has been used clinically more recently in China for the treatment of gastrointestinal tumors. CPT showed anticancer activity in preliminary clinical trials, especially against breast, ovarian, colon, lung, and stomach cancers. However, it has low solubility and adverse effects have been reported when used therapeutically, so synthetic and medicinal chemists have developed numerous syntheses of camptothecin and various derivatives to increase the benefits of the chemical, with good results. Four CPT analogues have been approved and are used in cancer chemotherapy today: topotecan, irinotecan, belotecan, and trastuzumab deruxtecan. Camptothecin has also been found in other plants including Chonemorpha fragrans.
In enzymology, a quinoprotein glucose dehydrogenase is an enzyme that catalyzes the chemical reaction
The enzyme 1,4-lactonase (EC 3.1.1.25) catalyzes the generic reaction
The enzyme 3-oxoadipate enol-lactonase (EC 3.1.1.24) catalyzes the reaction
The enzyme D-arabinonolactonase (EC 3.1.1.30) the reaction
The enzyme deoxylimonate A-ring-lactonase (EC 3.1.1.46) catalyzes the reaction
The enzyme gluconolactonase (EC 3.1.1.17) catalyzes the reaction
The enzyme L-arabinonolactonase (EC 3.1.1.15) catalyzes the reaction
The enzyme L-rhamnono-1,4-lactonase (EC 3.1.1.65) catalyzes the reaction
The enzyme triacetate-lactonase (EC 3.1.1.38) catalyzes the reaction
The enzyme uronolactonase (EC 3.1.1.19) catalyzes the reaction
The enzyme xylono-1,4-lactonase (EC 3.1.1.68) catalyzes the reaction
The enzyme amygdalin β-glucosidase (EC 3.2.1.117) catalyzes the following chemical reaction:
In enzymology, a glucosylceramidase (EC 3.2.1.45) is an enzyme that catalyzes the chemical reaction
Lactonase (EC 3.1.1.81, acyl-homoserine lactonase; systematic name N-acyl-L-homoserine-lactone lactonohydrolase) is a metalloenzyme, produced by certain species of bacteria, which targets and inactivates acylated homoserine lactones (AHLs). It catalyzes the reaction
The enzyme monoterpene ε-lactone hydrolase (EC 3.1.1.83, MLH; systematic name isoprop(en)ylmethyloxepan-2-one lactonohydrolase catalyses the reaction
Cobalt-precorrin 5A hydrolase (EC 3.7.1.12), CbiG (gene)) is an enzyme with systematic name cobalt-precorrin 5A acylhydrolase. This enzyme catalyses the following chemical reaction
Lipase inhibitors belong to a drug class that is used as an antiobesity agent. Their mode of action is to inhibit gastric and pancreatic lipases, enzymes that play an important role in the digestion of dietary fat. Lipase inhibitors are classified in the ATC-classification system as A08AB . Numerous compounds have been either isolated from nature, semi-synthesized, or fully synthesized and then screened for their lipase inhibitory activity but the only lipase inhibitor on the market is orlistat . Lipase inhibitors have also shown anticancer activity, by inhibiting fatty acid synthase.